The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Open accessAbstract
Although standard anticancer chemotherapeutic drugs have been designed to inhibit the survival or growth of rapidly dividing tumor cells, it is possible to enhance the efficacy of such drugs by targeting the proliferating host endothelial cells (ECs) of the tumor vasculature. A theoretical advantage of this strategy lies in the possibility of circumventing, or significantly delaying, acquired drug resistance driven by the genetic instability of tumor cells. Here, we show that both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor significantly reduce the pro-apoptotic potency of chemotherapy on both micro- and macrovascular ECs. This cytoprotection to drug toxicity was found to be phosphatidylinositol 3-kinase-dependent and could be recapitulated in the absence of VEGF by overexpressing the dominant-active form of the serine/threonine kinase protein kinase B/Akt. Downstream of phosphatidylinositol 3-kinase, we also show that survivin plays a pivotal role in VEGF-mediated EC protection by preserving the microtubule network. In this respect, its induction effectively protects ECs against chemotherapeutic damage, whereas overexpression of its dominant-interfering mutant (C84A) abrogates the protective effects of VEGF. Accordingly, the potency of VEGF as a chemoprotectant was more pronounced with drugs that interfere with microtubule dynamics than those that damage DNA. These studies implicate a role for survivin up-regulation as a novel mechanism of EC drug “resistance” and support the notion that angiogenic factors that induce the expression of survivin may act to shield tumor ECs from the apoptotic effects of chemotherapy. Thus, exploiting chemotherapeutic drugs as antiangiogenics is likely to be compromised by the high concentrations of proangiogenic survival/growth factors present in the tumor microenvironment; targeting EC survival pathways should improve the antiangiogenic efficacy of antineoplastic agents, particularly microtubule-inhibitor drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Control of apoptosis and mitotic spindle checkpoint by survivin
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., & Altieri, D. C. (1998) · Nature · doi:10.1038/25141 · Cited by 1,870
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., & Keshet, E. (1995) · Nature Medicine · doi:10.1038/nm1095-1024 · Cited by 1,604
Tamm, I., Wang, Y., Sausville, E. A., Scudiero, D. A., Vigna, N. J., Oltersdorf, T., & Reed, J. C. (1998) · PubMed · Cited by 1,397
Mechanisms and consequences of activation of protein kinase B/Akt
Downward, J. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80149-x · Cited by 1,303
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationSignals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/71517 · Cited by 1,020
Gerber, H.-P., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13313 · Cited by 981
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Structural basis for phosphoserine-proline recognition by group IV WW domains.
Verdecia, M. A., Bowman, M. E., Lu, K. P., Hunter, T. R., & Noel, J. P. (2000) · Nature Structural Biology · doi:10.1038/77929 · Cited by 704
Combined effects of angiostatin and ionizing radiation in antitumour therapy
Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M.-J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., et al. (1998) · Nature · doi:10.1038/28412 · Cited by 668
Kim, I., Kim, H. G., So, J.-N., Kim, J. H., Kwak, H. J., & Koh, G. Y. (2000) · Circulation Research · doi:10.1161/01.res.86.1.24 · Cited by 649
Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway
Papapetropoulos, A., Fulton, D., Mahboubi, K., Kalb, R. G., O'Connor, D. S., Li, F., Altieri, D. C., & Sessa, W. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9102 · Cited by 641
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Self-citationEffect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
Self-citationRedefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells
O'Connor, D. S., Schechner, J. S., Adida, C., Mesri, M., Rothermel, A. L., Li, F., Nath, A. K., Pober, J. S., & Altieri, D. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64742-6 · Cited by 341
Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement.
Noel, J. P., Verdecia, M. A., Huang, H.-K., Sonnenburg, E. D., Kaiser, D. A., & Hunter, T. R. (2000) · Nature Structural Biology · doi:10.1038/76838 · Cited by 337
Cancer gene therapy using a survivin mutant adenovirus
Mesri, M., Wall, N. R., Li, J., Kim, R. W., & Altieri, D. C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12983 · Cited by 337
Geng, L., Donnelly, E. F., McMahon, G., Lin, P. C., Sierra‐Rivera, E., Oshinka, H., & Hallahan, D. E. (2001) · PubMed · Cited by 334
Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., & Kerbel, R. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1589 · Cited by 333
Self-citationSweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001) · PubMed · Cited by 331
Fortugno, P., Wall, N. R., Giodini, A., O'Connor, D. S., Plescia, J., Padgett, K. M., Tognin, S., Marchisio, P. C., & Altieri, D. C. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.3.575 · Cited by 307
Guo, N., Krutzsch, H. C., Inman, J. K., & Roberts, D. D. (1997) · PubMed · Cited by 293
Nor, J. E., Christensen, J. B., Liu, J., Peters, M., Mooney, D. J., Strieter, R. M., & Polverini, P. J. (2001) · PubMed · Cited by 257
Angiopoietin‐1 is an apoptosis survival factor for endothelial cells
Kwak, H. J., So, J.-N., Lee, S. J., Kim, I., & Koh, G. Y. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00378-6 · Cited by 239
Mesri, M., Morales-Ruiz, M., Ackermann, E. J., Bennett, C. F., Pober, J. S., Sessa, W. C., & Altieri, D. C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64131-4 · Cited by 183
‘Accidental’ anti-angiogenic drugs
Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182
Self-citationKarsan, A., Yee, E., Poirier, G. G., Zhou, P., Craig, R. W., & Harlan, J. M. (1997) · Europe PMC (PubMed Central) · Cited by 180
Effects of Survivin Antagonists on Growth of Established Tumors and B7-1 Immunogene Therapy
Kanwar, J. R., Shen, W.-P., Kanwar, R. K., Berg, R. W., & Krissansen, G. W. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.20.1541 · Cited by 172
Flusberg, D. A., Numaguchi, Y., & Ingber, D. E. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.10.3087 · Cited by 111
Yu, J., Rak, J. W., Klement, G. L., & Kerbel, R. S. (2002) · PubMed · Cited by 97
Self-citation
Cited by
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
Celli, J. P., Spring, B. Q., Rizvi, I., Evans, C. L., Samkoe, K. S., Verma, S., Pogue, B. W., & Hasan, T. (2010) · Chemical Reviews · doi:10.1021/cr900300p · Cited by 2,324
PI3K/AKT/mTOR Pathway in Angiogenesis
Karar, J., & Maity, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00051 · Cited by 1,461
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Self-citation
Metadata
- Authors
- Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., & Kerbel, R. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-03-26
- Volume
- 99
- Issue
- 7
- Pages
- 4349-4354
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2163453798
- Cited by
- 434
- References
- 33
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.